4.5 Article

A sensitive UHPLC-MS/MS method for the simultaneous quantification of three lignans in human plasma and its application to a pharmacokinetic study

期刊

JOURNAL OF SEPARATION SCIENCE
卷 40, 期 17, 页码 3430-3439

出版社

WILEY-V C H VERLAG GMBH
DOI: 10.1002/jssc.201700588

关键词

gomisin N; human plasma; schizandrin; schizandrol B; ultra high performance liquid chromatographytandem mass spectrometry

资金

  1. Jeollanam-Do Development Institute for Korean Traditional Medicine (JKTM) grant - Korean government (MOHW)

向作者/读者索取更多资源

The aim of this study was to develop an analytical method to simultaneously analyze schizandrin, schizandrol B, and gomisin N lignans in human plasma using ultra high performance liquid chromatography with tandem mass spectrometry. The three lignans were separated using a mobile phase of water and acetonitrile containing 0.02% acetic acid equipped with a Kinetex C-18 column (2.1 mm x 50 mm, 1.7 mu m). This analysis was achieved by multiple reaction monitoring mode in an electrospray interface. The mass transitions were m/z 433.1 -> 384.0 for schizandrin, 398.8 -> 367.8 for schizandrol B, and 400.6 -> 299.8 for gomisin N. Liquid-liquid extraction with methyl tert-butyl ether was used to obtain the three lignans. The chromatograms showed high resolution, sensitivity, and selectivity with no interference with plasma constituents. The calibration curves for the three lignans in human plasma were 0.05-50 ng/mL and displayed excellent linearity with correlation coefficients greater than 0.99. Precision for all three lignans was within 11.23%. The accuracy was 88.3-99.0% for schizandrin, 90.6-103.4% for schizandrol B, and 90.2-103.5% for gomisin N. The developed simultaneous analytical method satisfied the criteria of international guidance and could be successfully applied to the pharmacokinetic study of three lignans after oral administration of Schisandrae Fructus extract powder to humans.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据